<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545335</url>
  </required_header>
  <id_info>
    <org_study_id>HCV-neutrophil</org_study_id>
    <nct_id>NCT02545335</nct_id>
  </id_info>
  <brief_title>Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C</brief_title>
  <official_title>Neutrophil Function During Combination Therapy With Protease Inhibitors in Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to characterize neutrophil function in patients undergoing chronic&#xD;
      hepatitis C triple therapy with protease inhibitors in comparison to dual therapy with&#xD;
      peginterferon and ribavirin and with interferon free treatment regimen to thereby elucidate&#xD;
      the possible mechanisms of protease-inhibitor associated infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C infection (CHC) is a major health problem, potentially leading to liver&#xD;
      related mortality via complications of liver cirrhosis or hepatocellular carcinoma, and&#xD;
      affects more than 185 million persons worldwide. Antiviral therapy evolved during the past 25&#xD;
      years from standard interferon, the combination with ribavirin and pegylated interferon (P/R)&#xD;
      to the addition of protease inhibitors and is currently on the edge to an interferon-free era&#xD;
      with the first such substances being approved in 2014. However, current standard therapy for&#xD;
      CHC genotype 1 patients without cirrhosis consists of ribavirin and pegylated interferon&#xD;
      (P/R) in combination with boceprevir (BOC) or telaprevir (TPV), which are direct acting&#xD;
      antivirals and represent the first-generation protease inhibitors.&#xD;
&#xD;
      Triple therapy for CHC has been reported to be associated with a quantitative and qualitative&#xD;
      increase in treatment-related (serious) adverse events compared to the former standard&#xD;
      therapy without protease-inhibitors. Moreover, reports of serious infectious complications&#xD;
      during triple therapy - especially in patients with acquired immune deficiencies like liver&#xD;
      cirrhosis - that lead to considerable morbidity and mortality, have accumulated recently. The&#xD;
      mechanisms of this increased susceptibility to infections remain unclear. However, BOC is&#xD;
      known to inhibit neutrophil elastase activity.&#xD;
&#xD;
      Aims of this study were therefore to analyse infections that occurred in CHC outpatients&#xD;
      during therapy in the study centre, to prospectively characterize neutrophil function in&#xD;
      patients undergoing CHC triple therapy in comparison to dual therapy with peginterferon and&#xD;
      ribavirin and to thereby elucidate the possible mechanisms of protease-inhibitor associated&#xD;
      infections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>neutrophil phagocytosis</measure>
    <time_frame>12 weeks</time_frame>
    <description>phagocytosis of labelled E.coli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of infections</measure>
    <time_frame>12 weeks</time_frame>
    <description>reported infections</description>
  </secondary_outcome>
  <enrollment type="Actual">174</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with chronic hepatitis C undergoing antiviral therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic hepatitis C&#xD;
&#xD;
          -  planned antiviral therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immunosuppressive medication&#xD;
&#xD;
          -  active infection at baseline&#xD;
&#xD;
          -  treatment with antibiotics within the last two weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Statdlbauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Spindelboeck W, Horvath A, Tawdrous M, Schmerböck B, Zettel G, Posch A, Streit A, Jurse P, Lemesch S, Horn M, Wuensch G, Stiegler P, Stauber RE, Leber B, Stadlbauer V. Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes. PLoS One. 2016 Mar 3;11(3):e0150299. doi: 10.1371/journal.pone.0150299. eCollection 2016.</citation>
    <PMID>26938078</PMID>
  </results_reference>
  <results_reference>
    <citation>Leber B, Balázs I, Horvath A, Posch A, Streit A, Spindelböck W, Feldbacher N, Stiegler P, Stauber RE, Rechberger GN, Kollroser M, Sattler W, Nusshold C, Stadlbauer V. Direct acting antiviral therapy rescues neutrophil dysfunction and reduces hemolysis in hepatitis C infection. Transl Res. 2021 Jun;232:103-114. doi: 10.1016/j.trsl.2020.12.005. Epub 2020 Dec 19.</citation>
    <PMID>33352296</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>September 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

